Literature DB >> 12931142

Pharmacological and nonpharmacological factors influencing hypothalamic-pituitary-adrenocortical axis reactivity in acutely depressed psychiatric in-patients, measured by the Dex-CRH test.

H E Künzel1, E B Binder, T Nickel, M Ising, B Fuchs, M Majer, A Pfennig, G Ernst, N Kern, D A Schmid, M Uhr, F Holsboer, S Modell.   

Abstract

The most consistent biological findings in patients with depression are abnormalities in the hypothalamic-pituitary-adrenal (HPA)-axis, which can be measured using the combined dexamethasone-suppression/CRH-stimulation (Dex-CRH) test. The reactivity of the HPA-axis in this test, however, ranges over several orders of magnitude in depressed patients with comparable severity of symptoms. In this present study, we investigate which factors influence the magnitude of the response in the Dex-CRH test in 235 acutely depressed in-patients. We first examined the effects of common confounders shown to influence the HPA-axis, such as caffeine and nicotine consumption, acute stressors during the test, weight, gender, and age. Of all these variables, only female sex and nicotine consumption were positively correlated with the cortisol or ACTH response, respectively. As for the effects of psychopharmacological treatment, only the intake of carbamazepine and the fact of having relapsed under an established pharmacotherapy significantly increased the response in the Dex-CRH test, whereas the presence or absence of antidepressant treatment, the type of antidepressant treatment, or the number of ineffective antidepressant treatment trials during the index episode up to admission did not have any effect. We also found a positive correlation of the number of previous episodes, the overall HAM-D score and the severity of somatic/vegetative symptoms with the results in the Dex-CRH test. These results underline that in depressed patients this test is not majorly influenced by disease-unrelated factors. In addition, current antidepressant treatment does not appear to affect test outcome in the absence of clinical response. The influence of the number of previous episodes and relapse under pharmacotherapy suggests that HPA-axis reactivity may be altered by repetitive states of hypercortisolemia or continuous antidepressant treatment. Finally, more severe vegetative symptoms are associated with an enhanced HPA-axis activity.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12931142     DOI: 10.1038/sj.npp.1300280

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  27 in total

1.  Time course of hypothalamic-pituitary-adrenocortical axis activity during treatment with reboxetine and mirtazapine in depressed patients.

Authors:  Cornelius Schüle; Thomas C Baghai; Daniela Eser; Peter Zwanzger; Martina Jordan; Renate Buechs; Rainer Rupprecht
Journal:  Psychopharmacology (Berl)       Date:  2006-04-22       Impact factor: 4.530

Review 2.  Endocrine disturbances in depression.

Authors:  M A Tichomirowa; M E Keck; H J Schneider; M Paez-Pereda; U Renner; F Holsboer; G K Stalla
Journal:  J Endocrinol Invest       Date:  2005-01       Impact factor: 4.256

Review 3.  Reliability of hypothalamic-pituitary-adrenal axis assessment methods for use in population-based studies.

Authors:  Sherita Hill Golden; Gary S Wand; Saurabh Malhotra; Ihab Kamel; Karen Horton
Journal:  Eur J Epidemiol       Date:  2011-04-30       Impact factor: 8.082

Review 4.  A users guide to HPA axis research.

Authors:  Robert L Spencer; Terrence Deak
Journal:  Physiol Behav       Date:  2016-11-18

5.  The circadian basis of winter depression.

Authors:  Alfred J Lewy; Bryan J Lefler; Jonathan S Emens; Vance K Bauer
Journal:  Proc Natl Acad Sci U S A       Date:  2006-04-28       Impact factor: 11.205

6.  Gender-specific association of galanin polymorphisms with HPA-axis dysregulation, symptom severity, and antidepressant treatment response.

Authors:  Paul G Unschuld; Marcus Ising; Darina Roeske; Angelika Erhardt; Michael Specht; Stefan Kloiber; Manfred Uhr; Bertram Müller-Myhsok; Florian Holsboer; Elisabeth B Binder
Journal:  Neuropsychopharmacology       Date:  2010-03-17       Impact factor: 7.853

Review 7.  Interactions between antidepressants and P-glycoprotein at the blood-brain barrier: clinical significance of in vitro and in vivo findings.

Authors:  Fionn E O'Brien; Timothy G Dinan; Brendan T Griffin; John F Cryan
Journal:  Br J Pharmacol       Date:  2012-01       Impact factor: 8.739

8.  Acute HPA axis response to naltrexone differs in female vs. male smokers.

Authors:  Daniel J O Roche; Emma Childs; Alyssa M Epstein; Andrea C King
Journal:  Psychoneuroendocrinology       Date:  2009-10-17       Impact factor: 4.905

9.  Atypical depression is more common than melancholic in fibromyalgia: an observational cohort study.

Authors:  Rebecca L Ross; Kim D Jones; Rachel L Ward; Lisa J Wood; Robert M Bennett
Journal:  BMC Musculoskelet Disord       Date:  2010-06-14       Impact factor: 2.362

10.  Polymorphisms in GRIK4, HTR2A, and FKBP5 show interactive effects in predicting remission to antidepressant treatment.

Authors:  Sonja Horstmann; Susanne Lucae; Andreas Menke; Johannes M Hennings; Marcus Ising; Darina Roeske; Bertram Müller-Myhsok; Florian Holsboer; Elisabeth B Binder
Journal:  Neuropsychopharmacology       Date:  2009-11-18       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.